BRAF and melanoma: Taking A375 advanced melanoma cells as an example, we detected and validated mutations in BRAF, FGFR2 and mTOR that could reasonably be expected to associate with Vemurafenib (BRAFi (V), hereafter), Vargatef (FGFR2i (Va)) and Everolimus (mTORi (E)).